IPA News

April 11th, 2025

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to phase out animal testing requirements...

March 13th, 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics

Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas - ImmunoPrecise Antibodies Ltd....

February 26th, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering...

February 24th, 2025

ImmunoPrecise Antibodies Announces Key Leadership Changes

AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev...

January 22nd, 2025

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment.

AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes...

January 17th, 2025

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial...

November 13th, 2024

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, BRITISH COLUMBIA (CANADA), November 13, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or...

November 4th, 2024

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

VICTORIA, BRITISH COLUMBIA (CANADA), November 4, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA),an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday,...

October 28th, 2024

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, BRITISH COLUMBIA (CANADA), October 28, 2024 – ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an...

October 21st, 2024

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation...

October 10th, 2024

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics VICTORIA, BRITISH COLUMBIA (CANADA), October 10, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)...

October 2nd, 2024

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUAI, (CHINA), October 2, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an...

September 26th, 2024

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

Rabbit B Cell Select ® Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)...

August 19th, 2024

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

Engineering antibodies in silico using LENSai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. Key...

June 27th, 2024

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

VICTORIA, BRITISH COLUMBIA (CANADA), June 27, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief...

June 25th, 2024

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating...

June 12th, 2024

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

VICTORIA, British Columbia, June 12, 2024 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand,...

June 10th, 2024

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. ...

June 4th, 2024

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)

Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, BRITISH COLUMBIA (CANADA), June 04, 2024 – IPA (IMMUNOPRECISE...

March 28th, 2024

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

VICTORIA, BRITISH COLUMBIA (CANADA), March 28, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical...

March 20th, 2024

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. VICTORIA, BRITISH COLUMBIA (CANADA), March 20, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), ...

March 7th, 2024

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, BRITISH COLUMBIA (CANADA), March 7, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.)...

December 14th, 2023

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*

VICTORIA, BRITISH COLUMBIA (CANADA), December 14, 2023 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results...

November 27th, 2023

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

VICTORIA, British Columbia, November 27, 2023 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director...

November 13th, 2023

BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research

VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary,...

October 25th, 2023

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

Company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. Significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million dollars, another...

September 8th, 2023

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

The Company to host an earnings conference call via webcast VICTORIA, British Columbia, September 8 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today...

September 5th, 2023

IPA Announces Board Refreshment

PA appoints Barry A. Springer, Dirk Witters and Chris Buyseto the Board of Directors VICTORIA, British Columbia, September 5 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and...

August 9th, 2023

IPA Responds to 13D Filing

IPA responds to 13D Filing by Ingalls & Snyder, LLC VICTORIA, British Columbia, August 9 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the...

July 14th, 2023

ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research

VICTORIA, British Columbia, July 14 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to...

July 7th, 2023

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded...

June 29th, 2023

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.

The Company to host an earnings conference call via webcast VICTORIA, British Columbia, June 29, 2023 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today...

June 13th, 2023

IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

VICTORIA, British Columbia, June 13, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration...

June 6th, 2023

IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

VICTORIA, British Columbia, June 6, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and...

May 30th, 2023

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has...

April 24th, 2023

LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT™ technology to enhance LLMs and accelerate antibody discovery.

Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a transformative moment in biotechnology." See full announcement

March 30th, 2023

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSᵃⁱ® Integrated Intelligence Technology®, Built Upon the...

March 27th, 2023

European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020. Patent Application Covers a Method to Efficiently...

March 23rd, 2023

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR) ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B...

March 16th, 2023

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

IPA’s Project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary B cell Select® platform and protein manufacturing services. Talem Therapeutics has announced a collaboration with Libera Bio to...

March 15th, 2023

ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®) The Alliance has Stipulated a Minimum of Upfront and Downstream Milestone...

December 15th, 2022

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Scale Modeling (ESM)-2 Fold HYFTs are now linked together by more...

December 8th, 2022

IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFT™ and Accelerates in Silico Drug Discovery Developments

Structural HYFT Technology is used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Scale Modeling (ESM)-2 Fold HYFT Technology explores formal and explicit biologically relevant knowledge and...

November 29th, 2022

IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV...

November 22nd, 2022

ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

VICTORIA, BRITISH COLUMBIA (CANADA), November 22, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares...

October 12th, 2022

IPA’s subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

Under strategic collaboration, Talem, an IPA subsidiary, expands its relationship with Ligand/OmniAb, Inc., to develop three immuno-oncology programs targeting validated targets Talem intends to leverage IPA’s broad range of advanced laboratory...

September 14th, 2022

NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75

VICTORIA, BRITISH COLUMBIA (CANADA), September 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results of a...

September 14th, 2022

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

Structural HYFTs fully indexed and integrated in structure-function workflow LENSai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once Company shares BioStrand...

August 29th, 2022

Live Virus Assays at Ludwig-Maximilians-Universität München Confirm Polytope’s Efficacy Against SARS-CoV-2 Variants Including BA.5

VICTORIA, BRITISH COLUMBIA (CANADA), August 29, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope®...

July 28th, 2022

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022

The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same period last...

July 28th, 2022

Capabilities deck

IPA_CapabilitiesDeck_2022

July 26th, 2022

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), July 26, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and...

July 12th, 2022

Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail agai

Milestone IPA Toxicity Study Supports the Safety of PolyTope® TATX-03 Antibody Cocktail Against COVID-19 IND-enabling safety evaluations of PolyTope® TATX-03, executed under Good Laboratory Practice (GLP) standards and regulatory guidelines,...

May 9th, 2022

IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs™ with 3D protein structure and function Diepenbeek, (Belgium), May 9, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is...

April 20th, 2022

IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Conce

• IPA’s Polytope® TATX-03 shows continuous validation of potent in vitro neutralizing activity against SARS-CoV-2 variants of concern, as further demonstrated against the Omicron sublineage BA.2 • Neutralization potency of the TATX-03 cocktail...

April 14th, 2022

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

VICTORIA, BRITISH COLUMBIA (CANADA), April 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand...

March 29th, 2022

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

New Platform Integrates Sequence Data and Information from Entire Biosphere • Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. • Platform is based on a proprietary biological discovery called HYFT™ patterns,...

March 16th, 2022

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022

VICTORIA, BRITISH COLUMBIA March 16, 2022 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for...

March 14th, 2022

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

• Companies to pursue a low-volume injectable formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03 • The new formulation, TATX-03E, aims to address the patient need for a stable, low-volume, self-injectable formulation that is...

March 9th, 2022

IPA Updates On Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

In vivo, IND enabling evaluations of PolyTope® TATX-03 in animal model show: • There were no pharmacokinetic aberrations • Injection with TATX-03 is well tolerated – with a significant safety margin and no clinical signs of toxicity • Maximum...

March 8th, 2022

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET

VICTORIA, BRITISH COLUMBIA March 8, 2022 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a...

January 31st, 2022

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission

• During in vitro pseudovirus assays, IPA’s PolyTope® advanced immunotherapeutic TATX-03 prevents infection of cells by SARS-CoV-2 variant-of-concern, Omicron, and all variants of concern tested to date. • On January 27, 2022, Talem Therapeutic...

January 18th, 2022

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

IPA Europe’s Oss laboratories make a move to new Centre of Excellence facilities in Oss, Netherlands, with progressive environmental impact measures. VICTORIA, BRITISH COLUMBIA and OSS, The Netherlands, January 17, 2022 / – IMMUNOPRECISE ANTIBODIES...

January 11th, 2022

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia – January 11, 2022 – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 7, 2022 its board of...

January 10th, 2022

2022 BIO Partnering at JPM

Join ImmunoPrecise for 2022 BIO Partnering at JPM. The event is being held virtually from January 10-14, 2022. This event provides attendees with tools to efficiently arrange meetings and make connections in the life science industry. To learn more...

January 9th, 2022

21st Annual PepTalk

ImmunoPrecise will be attending the 21st Annual PepTalk 2022, the Protein Science and Production Week, from January 17-19th, 2022. PepTalk is the largest annual gathering of protein science researchers in the world. The conference focuses on...

January 3rd, 2022

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia – January 3, 2022–IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the...

December 19th, 2021

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration

VICTORIA, BRITISH COLUMBIA December 20, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSX VENTURE: IPA) and ChemPartner Biologics Co. Ltd. (“ChemPartner”) today announced their global antibody manufacturing...

December 13th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

VICTORIA, BRITISH COLUMBIA December 13, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for...

December 7th, 2021

Antibody Engineering & Therapeutics – San Diego

ImmunoPrecise (IPA) will be attending the Antibody Engineering & Therapeutics conference being hosted December 12-16, 2021. Delivered as a Hybrid Event, available in-person at the Marriott Marquis San Diego as well as online. IPA will be hosting an...

December 7th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

The Company to host an earnings conference call via webcast on December 13, 2021 at the close of market VICTORIA, BRITISH COLUMBIA December 7th, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a...

November 29th, 2021

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program

Polytope™ Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis VICTORIA, BRITISH COLUMBIA (CANADA), November 30, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is providing an...

November 24th, 2021

The BioTech Pharma Summit

ImmunoPrecise (IPA) will be attending The BioTech Pharma Summit November 29-30, 2021 being held in Porto, Portugal and virtually. BioTech Pharma Summit brings together a large number of pharma industry buyers and sellers all under one roof. To learn...

November 24th, 2021

Europe HubXchange 2021

We will be attending Europe HubXchange on November 30, 2021. HubXchange specializes in delivering high-level content, intelligence, and connections to the global Life Sciences community by hosting outstanding business Xchanges. These meetings are a...

November 24th, 2021

ImmunoPrecise to present at The Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021

VICTORIA, BRITISH COLUMBIA (CANADA), Novembre 24, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference. The...

November 10th, 2021

IPA Announces Resignation of Director

VICTORIA, BRITISH COLUMBIA November 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective...

October 28th, 2021

European Antibody Congress

ImmunoPrecise Antibodies (IPA) will attend the Festival of Biologics held at the Congress Centre, Basel November 9-11th. The Festival of Biologics is a combination of four conferences: the European Antibody Congress, the World Immunotherapy...

October 14th, 2021

ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

VICTORIA, British Columbia, October 13, 2021, – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced that it has entered...

October 12th, 2021

13th Annual PEGS Europe

ImmunoPrecise will be exhibiting at the 13th annual PEGS Europe. PEGS (Protein & Antibody Engineering Summit) is one of the most significant European events for all aspects of proteins and antibody engineering, offering keynote speakers, seminars,...

October 12th, 2021

BIO-Europe

The international BIO-Europe® 2021 will be held digitally from October 25-28, 2021. BIO-Europe brings the global biopharma and investment leaders together to build partnerships and facilitate innovation and medical breakthroughs. ImmunoPrecise...

October 7th, 2021

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre

Multi-target research collaboration leverages ImmunoPrecise’s powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology VICTORIA, BRITISH COLUMBIA (CANADA) and CASTRES (FRANCE), October 07, 2021 –...

September 28th, 2021

Immuno-Oncology Summit

ImmunoPrecise (IPA) will be exhibiting at the Immuno-Oncology Summit in Boston on October 4-6, 2021. The event is being held at the Westin Copley Place and virtually. Visit booth 22 and learn how IPA can accelerate your immuno-oncology programs. The...

September 9th, 2021

19th Annual Discovery on Target

ImmunoPrecise Antibodies (IPA) will be participating in the 19th Annual Discovery on Target (DOT), being held in Boston, MA, and virtually, September 27-30. The event will host a variety of keynote speakers, short courses, roundtables, and...

September 9th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, BRITISH COLUMBIA September 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for...

September 8th, 2021

ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

VICTORIA, BRITISH COLUMBIA September 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss,...

September 7th, 2021

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

VICTORIA, September 7, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C....

September 3rd, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, BRITISH COLUMBIA September 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a...

August 4th, 2021

ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans

Barry Duplantis, Ph.D., promoted to VP of Client Relations Carla Dahl, appointed to VP of Marketing VICTORIA, BRITISH COLUMBIA August 4, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in...

July 28th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021

• Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020• Successfully dual listed to Nasdaq Global Market, subsequently raised USD$25 million in bought deal offering• Advanced proof-of-concept for TATX-03 COVID-19 program lead...

July 21st, 2021

ImmunoPrecise’s PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

IPA publishes its scientific paper “Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Protein with in vivo Efficacy” on bioRxiv VICTORIA, BRITISH COLUMBIA July 22,...

July 19th, 2021

Immunology 101: Innate and Adaptive Immunity Explained

Our body has a powerful army that protects it from various types of threats including viruses, bacteria, fungi, and parasites: this is the immune system. It has long been known that people who survive an infectious disease will develop protection...

July 15th, 2021

ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

The Company to host an earnings conference call via webcast on July 28, 2021, after the close of market VICTORIA, BRITISH COLUMBIA July 15, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in...

June 22nd, 2021

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

VICTORIA, BRITISH COLUMBIA, June 22, 2021 / – IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider...

June 17th, 2021

Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction

Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies -New histopathology data show that the significantly reduced viral load observed after prophylactic and therapeutic treatment with TATX-03a is...

June 16th, 2021

6th Annual CAR-TCR Summit

The 6th Annual CAR-TCR Summit returns in 2021 as the industry-leading comprehensive forum with one goal: to engineer a disease-free world. At the event, over 150 speakers will lead discussions on many topics from commercial pipeline development to...

June 15th, 2021

Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event

VICTORIA, BRITISH COLUMBIA, June 15, 2021 / – IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating TATX-21, a novel potential first-in-class...

June 12th, 2021

Upcoming Webinar Hosted by the Antibody Society

Dr. Debby Kruijsen and Dr. Ilse Roodink will be presenting the webinar Staying ahead of the virus: From a multispecies discovery strategy to highly efficacious, clinically suitable multi-antibody cocktails targeting SARS-CoV-2, June 17th at 8 am...

June 10th, 2021

Biologics UK: In-Person

ImmunoPrecise will be attending Europe’s premier meeting for biologics and R&D, Biologics UK, September 6th-7th (+Digital Day: September 8th), 2021 in London. Learn more about the event here

June 10th, 2021

HubXchange West Coast 2021

We will be attending US West Coast HubXchange from September 20th-22nd 2021. HubXchange specializes in delivering high-level content, intelligence and connections to the global Life Sciences community by hosting outstanding business Xchanges. These...

June 7th, 2021

ImmunoPrecise Team to attend BIO Digital

Dr. Michael Spring, Frederic Chabot, Dr. Barry Duplantis, and Timothy Miller of ImmunoPrecise will be attending BIO Digital June10-11 & June 14-18, 2021. The event will host multiple speakers and one-on-one partnering meetings. BIO Digital will...

June 6th, 2021

ImmunoPrecise to Present at Antibody Engineering & Therapeutics Europe

At this year’s Antibody Engineering & Therapeutics Europe, Dr. Debby Kruijsen will be present the scientific briefing Identification of Unique Antibodies by Parallel Sourcing Chicken and Human B-cell Repertoires Using Innovative Technologies. Our...

June 2nd, 2021

ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche

VICTORIA, BRITISH COLUMBIA June 2, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche,...

May 25th, 2021

ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

VICTORIA, BRITISH COLUMBIA May 25, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Dion Neame has...

May 20th, 2021

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

– Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment – Dr. Ilse Roodink and Dr. Debby Kruijsen to host live webinar “Function First: Using complementary...

May 10th, 2021

ImmunoPrecise attending HubXchange East 2021

ImmunoPrecise is attending HubXchange East being held in Boston May 17th-19th. HubXchange specializes in delivering high-level content, intelligence and connections to the global Life Sciences community by hosting outstanding business Xchanges....

April 28th, 2021

ImmunoPrecise To Attend Alliance For Cancer Gene Therapy Summit 2021

We are pleased to be attending the Alliance For Cancer and Gene Therapy Summit 2021. The summit is being held virtually April 29th 2021, containing multiple panels led by industry leaders to discuss the latest innovations in cancer drugs and...

April 27th, 2021

ImmunoPrecise Attending World Orphan Drug Congress

ImmunoPrecise will be attending the World Orphan Drug Congress, being held virtually April 28th, 2021. There will be a variety of panels and presentations throughout the day from industry experts. The conference is being held to advance the...

April 21st, 2021

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

VICTORIA, BRITISH COLOMBIA April 21, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and...

April 8th, 2021

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative Diseases VICTORIA, BRITISH COLUMBIA April 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic...

March 25th, 2021

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

• Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action • Binds to all tested variants of concern, likely because it targets a site other than the mutation prone Receptor Binding Domain/ACE2 binding interface...

March 17th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

• Immunoprecise and Genmab enter into a technology partnership targeting infectious disease • Immunoprecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation • Commenced trading on Nasdaq stock exchange • Announced...

March 16th, 2021

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy VICTORIA, BRITISH COLOMBIA March 16, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”)...

March 3rd, 2021

ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference)

Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK, S. African and Brazilian) VICTORIA, British Columbia, March 4, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a...

March 2nd, 2021

ImmunoPrecise To Participate in BiotechGate Digital Partnering Event

ImmunoPrecise will be participating in the Biotechgate Digital Partnering event being hosted virtually May 3-7, 2021. The digital partnering event is designed to support business development through pre-arranged 1-on-1 meetings. Learn more about the...

February 19th, 2021

ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19

• Treatment of Syrian hamsters with TATX-03, a cocktail of four proprietary monoclonal antibodies directed against distinct regions of the SARS-CoV-2 spike protein, resulted in strong anti-viral effects against SARS-CoV-2 in both protective and...

February 10th, 2021

IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares

VICTORIA, British Columbia, February 10, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment...

February 8th, 2021

IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares

VICTORIA, British Columbia, February 8, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, it has closed its...

February 3rd, 2021

IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million

VICTORIA, BRITISH COLUMBIA February 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, due to demand,...

February 3rd, 2021

IPA Announces $10.0 Million Bought Deal Offering of Common Shares

VICTORIA, BRITISH COLUMBIA February 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered...

January 7th, 2021

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, BC, January 6, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the grant of 25,000...

January 6th, 2021

ImmunoPrecise Antibodies to Participate in January Conferences

VICTORIA, British Columbia, January 6 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath, ImmunoPrecise’s Chief Executive Officer,...

December 29th, 2020

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through...

December 22nd, 2020

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

VICTORIA, December 23, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeutic antibody discovery and development, is pleased to announce that its common shares...

December 20th, 2020

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year

• Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 •Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform •Advanced Lead Candidates for COVID-19 PolyTope™...

December 13th, 2020

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

VICTORIA, December 14 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (TSXV:IPA) (OTCQB: IPATD) (FSE:TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax BV (Oss, the Netherlands), today announced the nomination...

December 10th, 2020

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

VICTORIA December 11, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a...

November 25th, 2020

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™

VICTORIA, November 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced it ranked 240 on ...

November 23rd, 2020

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

VICTORIA, November 23, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected more...

November 19th, 2020

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

VICTORIA, November 19, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into...

November 17th, 2020

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

VICTORIA, BC, November 17, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that, further...

November 9th, 2020

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

VICTORIA, BC, November 9, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has filed a...

November 4th, 2020

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

VICTORIA, BC, November 4, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it intends to...

November 3rd, 2020

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership

VICTORIA, November 3, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced a research partnership with...

October 27th, 2020

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

VICTORIA, October 27, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem...

October 8th, 2020

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

Also signs Definitive Commercial Agreement with University of Victoria VICTORIA, October 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic...

October 6th, 2020

IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO...

October 5th, 2020

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

VICTORIA, October 05, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO...

September 29th, 2020

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

VICTORIA, September 29, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2021 first quarter ended July 31, 2020. Q1 Fiscal 2021 Financial...

September 28th, 2020

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television

VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath,...

September 28th, 2020

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day

VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath,...

September 25th, 2020

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

VICTORIA, September 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, and LiteVax BV (Oss, the Netherlands), today announced...

September 22nd, 2020

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select™

VICTORIA, September 22, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, IPA...

September 17th, 2020

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

VICTORIA, September 17, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with...

September 10th, 2020

ImmunoPrecise Commences Application Process to Dual List on NASDAQ

VICTORIA, September 10, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) ( FSE:TQB2), a provider of best-in-class therapeutic antibody discovery capabilities for the global pharmaceutical and biotech...

September 9th, 2020

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

VICTORIA, September 9, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting...

September 8th, 2020

IPA CEO to Participate in Virtual Panel: “New Approaches to COVID-19: Hidden Breakthroughs,” on Thursday, September 10th

VICTORIA, September 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath,...

September 1st, 2020

ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020

Reports rapid advancement of COVID-19 antibody programs;combination studies achieve nearly complete neutralization of SARS-CoV-2 VICTORIA, August 31, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF)...

August 13th, 2020

IPA Appoints New York Based Crescendo Communications as Investor Relations and Corporate Communications

VICTORIA, August 13, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities announces that it has retained Crescendo Communications,...

July 31st, 2020

IPA’s Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization

VICTORIA, July 31, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to announce that additional characterization...

July 28th, 2020

IPA Awarded US$1.5M Bioscience Innovation Grant for Coronavirus Research from the North Dakota Department of Agriculture

VICTORIA, July 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a best-in-class therapeutic antibody discovery company for the global industry, is pleased to announce that the...

July 20th, 2020

IPA Announces Repayment of Remaining 2018 Debentures and $3,811,205 in Warrant Exercises

VICTORIA, July 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announces that it has repaid the...

July 13th, 2020

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA’s Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies

IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals’ genetically engineered OmniRat® strains producing human antibodies VICTORIA, July 13, 2020 / – IMMUNOPRECISE...

June 29th, 2020

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology VICTORIA, June 29, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF)...

June 22nd, 2020

Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2

Oss, Netherlands, June 22, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), and LiteVax BV (“LiteVax”) (the Netherlands), today announced that a preclinical study to analyze the...

June 11th, 2020

Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise’s European Subsidiary, UPE

Utrecht, June 11, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA, OTC QB: IPATF, Germany: TQB2) subsidiary U-Protein Express BV (“UPE”) today announced the availability of its new recombinant SARS-CoV-2...

June 4th, 2020

ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)

VICTORIA, June 4, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is...

May 27th, 2020

NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Respon

VICTORIA, May 27, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria...

May 19th, 2020

ImmunoPrecise Closes Oversubscribed Debenture Financing

VICTORIA, May 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has closed its previously announced non-brokered private placement financing by issuing a total of...

May 15th, 2020

ImmunoPrecise Increases Financing to $2.592 Million

VICTORIA, May 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has increased its previously announced (see news release dated April 24, 2020 and May 8, 2020)...

May 6th, 2020

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

VICTORIA, May 6, 2020 /- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced its laboratory in...

April 24th, 2020

ImmunoPrecise Updates on State and Federal Funding

IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens Fargo, April 24, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), is pleased to announce that the state of North Dakota has...

April 17th, 2020

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical trials. VICTORIA, April 17, 2020/ –...

April 15th, 2020

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

VICTORIA, April 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) provides an update on its participation and support of global solidarity in the fight against coronavirus. “Our scientific team is...

April 14th, 2020

ImmunoPrecise Announces Agreement with Janssen

VICTORIA, BC and CAMBRIDGE, MA, APRIL 14th, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its...

April 2nd, 2020

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

VICTORIA, April 2, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the...

March 30th, 2020

ImmunoPrecise’s Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope™ mAb Therapy Program

We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical...

March 12th, 2020

ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic

New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion VICTORIA, March 12, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), following its...

March 10th, 2020

ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA

VICTORIA, March 10, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2020 third quarter ended January 31, 2020. Revenue. The Company posted a...

March 9th, 2020

ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures

VICTORIA, March 6, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it wishes to settle up to $796,875 of previously issued debentures including interest by issuing up to 1,328,125...

March 2nd, 2020

ImmunoPrecise Announces Artificial Intelligence Collaboration With EVQLV To Accelerate Vaccine And Antibody Discovery For SARS-CoV-2 Coronavirus

The partnership with the New York-based artificial intelligence company will focus on high-throughput computational antibody design to derive novel leads from ImmunoPrecise’s platforms and accelerate Coronavirus therapeutic antibody discovery and...

February 20th, 2020

ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program

VICTORIA, BC, February 20, 2020 – ImmunoPrecise Antibodies Ltd (the “Company”), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment to the development of innovative vaccines...

January 20th, 2020

ImmunoPrecise integrates SGI-DNA’s benchtop automated DNA printer to accelerate antibody discovery and manufacturing services

VICTORIA, SAN DIEGO, and UTRECHT, January 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, and...

January 9th, 2020

ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe’s Most Competitive Science Region

VICTORIA and UTRECHT, January 09, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced...

January 6th, 2020

ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 13-16, 2020

VICTORIA, January 6, 2020/- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 38th Annual Healthcare Conference events running from January...

December 17th, 2019

ImmunoPrecise Announces Record Quarterly Revenue and Significantly Expands Gross Margins

VICTORIA, December 17, 2019/- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) announces today that it has released its financial results for the second quarter ended October 31, 2019. The financial statements...

December 3rd, 2019

ImmunoPrecise Announces Annual General Meeting Results

VICTORIA, December 2, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that all resolutions were passed by the shareholders at its annual general meeting (“AGM”) held in Vancouver,...

November 5th, 2019

Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

VICTORIA, November 05, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned...

October 18th, 2019

ImmunoPrecise Adopts Shareholder Rights Plan

VICTORIA, October 18, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that its Board of Directors has adopted a...

October 14th, 2019

ImmunoPrecise Exhibiting at European Antibody Congress in Basel, October 15-19, 2019

ImmunoPrecise Antibodies will attend the Festival of Biologics held at the Congress Centre, Basel October 15-19th. The Festival of Biologics is a combination of four incredible conferences, the European Antibody Congress, the World Immunotherapy...

October 3rd, 2019

ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

VICTORIA, October 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment...

October 1st, 2019

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

VICTORIA, October 1st, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment...

September 24th, 2019

ImmunoPrecise’s Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

VICTORIA, September 24, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, its wholly-owned...

September 22nd, 2019

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)

VICTORIA, September 23, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces its Abthena™ bispecific antibody platform and...

September 22nd, 2019

ImmunoPrecise to Lead Roundtable and Present Poster at 2019 West Coast Antibody Therapeutics Xchange

As innovative leaders in the field of antibody discovery, we are pleased to sponsor and lead group discussions at the 2019 West Coast Antibody Therapeutics Xchange. The unique format of hubXchange events formatting allows for a more in-depth...

September 16th, 2019

ImmunoPrecise Exhibiting at Discovery on Target in Boston, MA, on September 16-19

ImmunoPrecise Antibodies will participate in the 17th Annual Discovery on Target (DOT) being held Boston, MA September 16-19. With over 1,300 attendees and a variety of keynote speakers, training seminars, short courses, roundtables, and networking...

August 29th, 2019

ImmunoPrecise Antibodies’ Annual Revenues Increase 100% to $10,926,268 Million

VICTORIA, August 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for the year ended April 30, 2019. The financial statements and related Management’s...

August 7th, 2019

Shareholder Lab Visit: ImmunoPrecise Antibodies – Canada

ImmunoPrecise Antibodies Ltd invites our shareholders to visit our Victoria Lab on Wednesday, August, 14th, followed by a social at Canoe Brewpub in Downtown Victoria. Shareholders will have the opportunity to tour our labs and meet with Dr....

August 1st, 2019

ImmunoPrecise’s Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

VICTORIA, August 1, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces the launch of its High Value Target Scientific Committee which will strengthen the scientific oversight and...

July 15th, 2019

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

VICTORIA, June 12, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that it has entered into a new...

June 26th, 2019

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

VICTORIA, June 26, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that from this point forward it will...

June 10th, 2019

ImmunoPrecise Attending & Exhibiting at Antibody Engineering & Therapeutics Europe 2019

The ImmunoPrecise Antibodies team will be exhibiting at Antibody Engineering & Therapeutics (AET) Europe 2019 in Amsterdam, NL from June 11th-13th, 2019. AET Europe is the industry’s European meeting for Antibody and Protein Therapeutic Science,...

May 30th, 2019

ImmunoPrecise’s Diversified Offerings Spark Surge in Requests for use of Nine Different Transgenic Animal Strains on Innovative Service Platforms in B cell Select™️ and DeepDisplay™️

VICTORIA, May 30, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces that its proprietary, high-throughput B cell and phage display platforms have garnered a lot of attention as of...

April 25th, 2019

ImmunoPrecise Antibodies’ Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor

VICTORIA, APRIL 25, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) U-Protein Express, a wholly-owned ImmunoPrecise Antibodies subsidiary, in Utrech, Netherlands, announced that it has obtained an...

April 16th, 2019

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

VICTORIA, April 16, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today that Jennifer Bath, President and CEO of ImmunoPrecise Antibodies, will present at the upcoming 2019 Bloom...

April 11th, 2019

ImmunoPrecise Appoints Andy Nixon to Board of Directors

VICTORIA, April 11, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, as...

April 9th, 2019

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies

VICTORIA, April 9th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with TetraGenetics, a biopharmaceutical company developing novel...

April 5th, 2019

ImmunoPrecise Attending & Exhibiting at #PEGS 19 in Boston, April 8-11

The 2019 Protein Engineering Summit (PEGS) in Boston is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development. Plan to meet the IPA team at our booth (#622) to find out how to accelerate therapeutic...

April 4th, 2019

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

Victoria, British Columbia, Canada, April 03, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture...

April 4th, 2019

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

VICTORIA, April 4, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem Therapeutics (Talem). Talem is focused...

April 2nd, 2019

ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform – ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company

VICTORIA, April 2,2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery to select rare, fully human antibodies using...

March 28th, 2019

ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results – Revenues Up 228% For The First 9 Months of Fiscal 2019

VICTORIA, March 27, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q3 ended January 31, 2019. The financial statements and related management’s...

March 20th, 2019

Meet Us at European Antibody Therapeutics Xchange

ImmunoPrecise to Lead Scientific Round-table Discussion and Poster Session at hubXchange’s European Antibody Therapeutics event. At hubXchange’s European Antibody Therapeutics event, held in Munich on March 21st, Dr. Debby Kruijsen will lead a...

March 15th, 2019

ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV

VICTORIA, March 15, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today announces that Jos Raats, Ph.D., has resigned from the position of Managing Director of ModiQuest Research B.V. in order...

March 1st, 2019

ImmunoPrecise Antibodies Announces DTC Eligibility

VICTORIA, February 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository...

February 27th, 2019

Meet Us at the Americas Antibody Congress 2019

ImmunoPrecise will be exhibiting at the Americas Antibody Congress 2019 at Festival of Biologics, a multi-streamed, co-located conference & technology exhibition March 4 – 5, 2019 at the Grand Hyatt, in San Diego, California. Connect with us at...

February 21st, 2019

ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies

VICTORIA, February 21, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc.,...

February 19th, 2019

ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test

VICTORIA, February 19, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New...

February 14th, 2019

Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts.

VICTORIA, February 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office in Cambridge, Massachusetts. ImmunoPrecise Antibodies Ltd is a...

February 5th, 2019

ImmunoPrecise Antibodies Ltd. Increases Antibody Discovery Capabilities with Addition of Integrated Laboratory Equipment for High-throughput Antibody Screening

VICTORIA, February 4th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based...

January 14th, 2019

ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer

VICTORIA, January 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as Chief Financial Officer. Lisa Helbling brings over 30 years of...

January 8th, 2019

Meet Us at PepTalk 2019

ImmunoPrecise will be attending PepTalk 2019, the Protein Science Week, from January 14-18th, 2019. PepTalk is the largest annual gathering of protein science researchers in the world. The conference focuses on intensive learning to discover new...

January 3rd, 2019

ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019

VICTORIA, January 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 37th Annual Healthcare Conference events running from...

December 25th, 2018

ImmunoPrecise Hires Jason Orloske as Vice President Operations

VICTORIA, Dec. 26, 2018 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies...

December 6th, 2018

Meet Us at Antibody Engineering & Therapeutics 2018

ImmunoPrecise will be attending Antibody Engineering & Therapeutics 2018, the annual meeting of The Antibody Society, where you can find the latest science, technologies and partners in antibody engineering, immunobiology, and next generation...

November 26th, 2018

ImmunoPrecise Antibodies Ltd. Discusses Target Customer Base and Growth Drivers in an Interview with StockNewsNow

ImmunoPrecise’s CEO and President, Dr. Jennifer Bath spoke with SNNLive at the SmallCap Discoveries Conference 2018 in Vancouver. Check Out the Video to Find out More On: The overview and history of ImmunoPrecise Antibodies, what makes IPA unique in...

November 6th, 2018

Meet Us at the 10th Annual PEGS Summit Europe

ImmunoPrecise, ModiQuest Research, and U-Protein Express will be attending the 10th annual PEGS Summit Europe. PEGS (Protein & Antibody Engineering Summit) is the largest European event for all aspects of protein and antibody engineering, offering...

October 29th, 2018

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform

Victoria, British Columbia, Canada, October 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through our recent growth in Europe. Our advanced...

October 26th, 2018

European Antibody Congress 2018

ImmunoPrecise at European Antibody Congress 2018 ImmunoPrecise is excited to announce that we will be a part of the European Antibody Congress within the Festival of Biologics in Basel, Switzerland from October 29th to 31st. The European Antibody...

October 15th, 2018

ModiQuest to Offer Ligand’s OmniAb Service in Europe

Victoria, British Columbia, Canada, October 15th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is now an OmniAb approved CRO, which...

October 9th, 2018

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program...

October 2nd, 2018

ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms

Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offerings...

October 1st, 2018

Immunoprecise Antibodies’ Q1 Revenues Increase 386% Over Q1 2017

October 1st, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018. The financial statements and related management’s...

September 28th, 2018

ImmunoPrecise Closes Oversubscribed Private Placement Raising $9.1m

Victoria, British Columbia, Canada, September 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by...

September 24th, 2018

US West Coast Antibody Engineering Xchange 2018

ImmunoPrecise at US West Coast Antibody Engineering Xchange 2018 ImmunoPrecise is excited to announce that we will be attending hubXchange’s US West Coast Antibody Engineering Xchange in San Diego on September 26th, 2018. HubXchange specializes in...

September 21st, 2018

The Centre for Drug Research and Development (CDRD) selected ImmunoPrecise’s Chief Scientific Officer, Dr. Deanna Dryhurst as member of the CDRD Academy Executive Institute

Victoria, British Columbia, Canada, September 21st, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is proud to announce that our CSO, Dr. Deanna Dryhurst, has been selected as part of The CDRD...

September 21st, 2018

Meet with ImmunoPrecise at the 16th Annual Discovery on Target

ImmunoPrecise is excited to be exhibiting at this year’s Discovery on Target conference from September 25th to 28th in Boston, MA. Visit booth #213 at the Sheraton Boston, and discover how ImmunoPrecise can further your therapeutic antibody...

August 30th, 2018

ImmunoPrecise and Harbour Antibodies Announce Technology Co-offering Agreement for Next-Generation Fully-human Antibody Discovery

Co-offering Agreement combines ImmunoPrecise’s advanced hybridoma plus B cell screening and sorting services with Harbour Antibodies’ patented H2L2 transgenic mouse platform Victoria, British Columbia, Canada, August 30th, 2018 – IMMUNOPRECISE...

August 29th, 2018

ImmunoPrecise Antibodies’ Annual Revenues Increase 106% to 5.4 Million

August 29, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for the year ended April 30, 2018. The financial statements and related...

August 28th, 2018

ImmunoPrecise Increases Private Placement Financing to $7 Million

Victoria, British Columbia, Canada, August 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing (see...

August 22nd, 2018

ImmunoPrecise Announces $2 Million Financing

Victoria, British Columbia, Canada, August 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 2,000,000 units...

August 21st, 2018

ImmunoPrecise Announces the Resignation of Director

Victoria, British Columbia, Canada, August 20, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that Mr. Guy Champagne, has resigned from his position as a director, effective immediately,...

July 18th, 2018

ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility

VICTORIA, July 18, 2018 /CNW/ – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division...

June 19th, 2018

ImmunoPrecise Closes Private Placement Financing

Victoria, British Columbia, Canada, June 19, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by...

June 4th, 2018

Antibody Engineering & Therapeutics Europe June 5th-7th, 2018 – Meet with ImmunoPrecise & ModiQuest Research

ImmunoPrecise & ModiQuest Reseach B.V. will be exhibiting at the upcoming Antibody Engineering & Therapeutics Europe in Amsterdam! Come visit us at Booth #10 Featured Services B cell Selection Technologies Advanced Hybridoma Development Antibody...

May 30th, 2018

ImmunoPrecise Increases Private Placement Financing

Victoria, British Columbia, Canada, May 30, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing (see...

May 29th, 2018

ImmunoPrecise Announces Private Placement Financing

Victoria, British Columbia, Canada, May 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 750,000 units...

May 28th, 2018

BIO International Convention June 4th-7th, 2018 – Meet with ImmunoPrecise

ImmunoPrecise will be at the upcoming BIO International Convention in Boston and looks forward to meeting with you. Featured Services B cell Selection Technologies Advanced Hybridoma Development Preferred OmniAb® Service Provider Phage Display ...

May 25th, 2018

ImmunoPrecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth

Victoria, British Columbia, Canada, May 24, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management and board members, it has appointed Jennifer...

May 18th, 2018

ImmunoPrecise Opens U.S. Headquarters in Fargo, North Dakota

Victoria, British Columbia, Canada, May 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo, North Dakota. The Fargo-Moorhead (FM) region has...

April 27th, 2018

ImmunoPrecise Opens New Full Service B-Cell Facility

Victoria, British Columbia, Canada, April 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening,...

April 6th, 2018

ImmunoPrecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”) financing in the principal amount...

April 6th, 2018

ImmunoPrecise Acquires Modiquest Research BV

Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and EfficiencyStrategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British...

April 3rd, 2018

Meet ImmunoPrecise at the Protein & Antibody Engineering Summit (PEGS) in Boston

ImmunoPrecise will be exhibiting at the upcoming PEGS Summit conference, April 30th to May 4th in Boston. Meet the Team Come say hello to our team at booth 618. Here are the IPA team members that will be attending. Teri Otto – VP, Marketing and...

March 29th, 2018

ImmunoPrecise Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins to 54%

March 28, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter ended January 31, 2018. The financial statements and...

March 16th, 2018

ImmunoPrecise Enters Into Definitive Agreement To Acquire Modiquest Research BV

Victoria, British Columbia, Canada, March 16, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into the definitive share purchase agreement (the...

February 8th, 2018

ImmunoPrecise Appoints New President and CEO

Victoria, British Columbia, Canada, February 8, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February...

January 27th, 2018

ImmunoPrecise Antibodies Grants Stock Options

VICTORIA, January 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV:IPA, Pink Sheets:IPATF) reports that, pursuant to the Company’s Stock Option Plan, the Board of Directors has authorized the granting of incentive stock options to...

January 18th, 2018

ImmunoPrecise Engages San Francisco Based Lightpath Capital as A Key Partner in its Financing Strategy

Victoria, British Columbia, Canada, January 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. (“LightPath”) to act as its financial advisor and...

January 2nd, 2018

ImmunoPrecise Antibodies Attending J.P. Morgan Healthcare Conference Week January 8-11, 2018

ImmunoPrecise will be attending the J.P. Morgan 36th Annual Healthcare Conference running from January 8-11, 2018 in San Francisco, California. Thirty-five years ago, J.P. Morgan launched Wall Street’s premier investor conference focused exclusively...

December 30th, 2017

ImmunoPrecise Antibodies Reports Second Quarter Results

December 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV: IPA, Pink Sheets: IPATF) today reports its financial results for the second quarter ended October 31, 2017 and provides a business update. The...

December 19th, 2017

ImmunoPrecise Adds Scientific Depth To Its Board Of Directors

Victoria, British Columbia, Canada, December 18, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce the appointment of Dr. Robert Burke to the Company’s Board of Directors. Dr. Robert D....

December 8th, 2017

Meet ImmunoPrecise at Antibody Engineering & Therapeutics 2017

If you will be attending the Antibody Engineering & Therapeutics show, make sure to stop by booth #219! This is a great opportunity to meet with our scientists, discuss your research, and start a conversation on how ImmunoPrecise would go about...

December 7th, 2017

ImmunoPrecise to Acquire ModiQuest Research BV

Victoria, British Columbia, Canada, December 7, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV (“ModiQuest”) whereby the...

November 20th, 2017

ImmunoPrecise Realigns Senior Management

Victoria, British Columbia, Canada, November 20, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the realignment of its senior management team as Dr. James Kuo, Chair of the Board, assumes the...

October 1st, 2017

ImmunoPrecise Antibodies Reports Q1 2018 Results

ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business. Increases Operational Efficiency and Expands Capacity to Scale Quickly September 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”)...

September 18th, 2017

Immunoprecise Awarded First Commercial Humanized Antibody Project From Established Biotech Company And Grants Stock Options

Victoria, British Columbia, Canada, September 18, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has been awarded its first significant commercial humanizing project from...

September 7th, 2017

ImmunoPrecise Antibodies Announces Dr. Oren Beske Joining The Executive Leadership Team and AGM Results

Victoria, British Columbia, Canada, September 7, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce that Oren Beske, Ph.D. has joined the company as of September 1, 2017 and will be...

August 29th, 2017

ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies

Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization (“CRO”) for developing human monocolonal...

August 24th, 2017

ImmunoPrecise Antibodies Reports 2017 Annual Results – Revenues Up 39% Over Fiscal 2016

Victoria, British Columbia, Canada, August 24, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) yesterday reported its financial results for the fourth quarter ended April 30, 2017 and provides a...

August 24th, 2017

ImmunoPrecise Completes Acquisition of U-Protein and Private Placement of $5.25 Million

Victoria, British Columbia, Canada, August 23, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV (“U-Protein”) whereby the Company has acquired...

August 11th, 2017

ImmunoPrecise Signs Definitive Agreement with U-Protein

Victoria, British Columbia, Canada, August 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, further to its news release dated July 4, 2017, it has signed a definitive agreement with U-Protein...

August 3rd, 2017

ImmunoPrecise Announces Expansion Into Humanizing Technologies and Platforms

Victoria, British Columbia, Canada, August 3, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has completed significant steps that enhance its ability to deliver humanized monoclonal...

August 2nd, 2017

ImmunoPrecise Increases Financing to $5.25 Million

Victoria, British Columbia, Canada, August 2, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to announce that it has further increased...

July 24th, 2017

ImmunoPrecise Increases Financing to $5.1 Million

Victoria, British Columbia, Canada, July 24, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to announce that it has increased its...

July 4th, 2017

ImmunoPrecise To Acquire U-Protein and Announces $4,000,000 Financing

Victoria, British Columbia, Canada, July 4, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with U-Protein Express BV (“U-Protein“) whereby the Company has...

June 5th, 2017

Immunoprecise Antibodies Opens New Antibody Production Laboratory To Increase Manufacturing Capacity

Victoria, British Columbia, Canada, June 5, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the opening of its new 3,200 square foot state of the art antibody production laboratory at...

April 11th, 2017

Immunoprecise Begins Humanized Antibody Development

Victoria, British Columbia, Canada, April 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the launch of a new research initiative. As part of its Research and Development Program, the...

March 31st, 2017

Immunoprecise Antibodies Reports Q3 2017 Financial Results –Revenues Up 70% For The First Nine Months Of Fiscal 2017

Victoria, British Columbia, Canada, March 30, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), today reports its financial results for the third quarter ended January 31, 2017 and provides a business update. The...

March 29th, 2017

Meet IPA at the 30th Annual CSI Conference April 7-10, 2017 – Banff, AB

Join us at the 30th Annual Canadian Society for Immunology Conference in beautiful Banff, AB, this April 7-10, 2017. Date: April 7 – 10, 2017 Location: The Banff Centre, Banff, AB Event Info: CSI 2017 Description: The Banff Centre is...

March 8th, 2017

Immunoprecise Adds Dr. David Kroeger As Senior Scientist; New Us Trading Symbol

Victoria, British Columbia, Canada, March 9, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, is pleased to announce that David...

February 28th, 2017

Immunoprecise Appoints Contact Financial for Investor Relations and Launches New Website For Its Custom Antibody Services

Victoria, British Columbia, Canada, March 1, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced that it has appointed...

January 22nd, 2017

Immunoprecise Antibodies Issues Letter To Shareholders

Victoria, British Columbia, Canada, January 23, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA), a life sciences technology and product company supplying custom antibodies, today announced that the President and Chief...

HUB ofBiotherapeuticIntelligence™

Antibody Discovery Services

Protein Production

Online Store

See our latest upcoming event

Connect with IPA

HUB ofBiotherapeuticIntelligence™

AI Technology

See our latest upcoming event

Connect with IPA

HUB ofBiotherapeuticIntelligence™

Applications

See our latest upcoming event

Connect with IPA

HUB ofBiotherapeuticIntelligence™

Resources

See our latest upcoming event

Connect with IPA

HUB ofBiotherapeuticIntelligence™

Company

News

See our latest upcoming event

Connect with IPA

In the News

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment.

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research

IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™

IPA Provides Update on Growth Strategy and Recent Share Price Movement

ImmunoPrecise Antibodies Announces CFO Transition

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

IPA Announces Board Refreshment

IPA Responds to 13D Filing

ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.

IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT™ technology to enhance LLMs and accelerate antibody discovery.

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFT™ and Accelerates in Silico Drug Discovery Developments

IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

IPA’s subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

Live Virus Assays at Ludwig-Maximilians-Universität München Confirm Polytope’s Efficacy Against SARS-CoV-2 Variants Including BA.5

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022

Capabilities deck

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail agai

HUB of
Biotherapeutic
Intelligence™

HUB of
Biotherapeutic
Intelligence™

HUB of
Biotherapeutic
Intelligence™

HUB of
Biotherapeutic
Intelligence™

HUB of
Biotherapeutic
Intelligence™